We recently discovered that the protein phosphatase 2A (PP2A) B55alpha subunit (PPP2R2A) is under-expressed in primary blast cells and is unfavorable for remission duration in AML patients. In this study, reverse phase protein analysis (RPPA) of 230 proteins in 511 AML patient samples revealed a strong correlation of B55alpha with a number of proteins including MYC, PKC alpha, and SRC. B55alpha suppression in OCI-AML3 cells by shRNA demonstrated that the B subunit is a PKCalpha phosphatase. B55alpha does not target SRC, but rather the kinase suppresses protein expression of the B subunit. Finally, the correlation between B55alpha and MYC levels reflected a complex stoichiometric competition between B subunits. Loss of B55alpha in OCI-AML3 cells did not change global PP2A activity and the only isoform that is induced is the one containing B56alpha. In cells containing B55alpha shRNA, MYC was suppressed with concomitant induction of the competing B subunit B56alpha (PPP2R5A). A recent study determined that FTY-720, a drug whose action involves the activation of PP2A, resulted in the induction of B55alpha In AML cells, and a reduction of the B subunit rendered these cells resistant to FTY-720. Finally, reduction of the B subunit resulted in an increase in the expression of miR-191-5p and a suppression of miR-142-3p. B55alpha regulation of these miRs was intriguing as high levels of miR-191 portend poor survival in AML, and miR-142-3p is mutated in 2% of AML patient samples. In summary, the suppression of B55alpha activates signaling pathways that could support leukemia cell survival.